Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04221945
Title Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

cervical adenosquamous carcinoma

cervical adenocarcinoma

cervical squamous cell carcinoma

Therapies

Cisplatin + Pembrolizumab

Cisplatin

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.